Charles River Laboratories’ Post

Tailored preclinical studies are equal parts art and science. Our customized testing services highlight the seamless integration of efficacy and safety and the practical advantages it brings to #medicaldevice and drug developers. Check out our unique approach that blends scientific literature with hands-on model development. https://hubs.ly/Q02spkcs0 #medicaldevices #customizedtesting #preclinicalstudies

When I ask VPs and CSOs in pharma and biotech, "How certain are you that your preclinical findings will translate to human trials?" the answer is usually: "Confident, but we haven’t tested beyond the model—IND requirements are met." However, clinical trials often reveal unexpected toxicity or lack of efficacy. Inoviem Scientific has seen this too often, but we have a game-changing solution. Our enabling technology and our access to any human diseased fresh tissues identifies the precise molecular pathways responsible for drug efficacy directly on such samples. This ensures a seamless transition from preclinical models to clinical reality. Want to know how we can make a difference in your drug development process? Message me to learn more. #drugdevelopment #clinicaltrial #translational #precisionmedicine

The Significance of Early Drug Discovery In the race to develop life-saving medications, the early stages of drug discovery are arguably the most critical. It is here that novel drug candidates are identified, screened, and optimized before their advancement to preclinical and clinical trials. These initial phases, typically taking up to a decade, are fraught with challenges, including high attrition rates and substantial resource demands. The traditional approach to early drug discovery relied heavily on trial and error, a process that, while scientifically driven, was laborious, time-consuming, and costly. However, the infusion of ML techniques has swiftly propelled the industry towards a more data-driven, predictive, and agile model of drug development. #ai #drugs #health

🔍 Traditional drug development limits drug discovery: 💰 High costs are required to establish and maintain screening platforms with large libraries of compounds ❌ High risk of drug candidate failure due to safety or efficacy issues identified along the development lifecycle 📉 Missed opportunities as the capacity to analyze drug candidates can be limited to a relatively small and sub-optimal sample size Take a look at how our Deep Docking AI Platform is a game-changer and learn more on our corporate presentation 👇 https://bit.ly/3YDusFb #RakovinaTherapeutics #Biopharma #TSXV #Investing #CancerDrugs

Stay informed about deep-tech advances in drug discovery and biotech. Subscribe to our newsletter (link in the comments) #biopharmatrend

I'm excited to share our recently published paper in Expert Opinion on Drug Discovery (https://lnkd.in/gtAapGVR). This review highlights the impact of tautomerism on the predicted and clinically observed properties of small molecules that are crucial for drug design and patient drug behavior. We provide examples illustrating its effects on both pharmacokinetics and pharmacodynamics. Additionally, the significance of tautomerism in drug formulation and the potential interconversion of stereoisomers are discussed. This work represents the collective efforts of Marc Nicklaus and our team, including myself, DK Dhaked.

#LinkedIn friends and colleagues: I need your help. I’m exploring approaches to enhance preclinical efficacy testing in respiratory drug development, particularly through organ-on-chip technology and AI. While I’m reaching out to gather diverse perspectives, I understand you might know other experts in this area. Would you be open to a 15-minute conversation to share insights or refer colleagues knowledgeable in this field? Your input would be invaluable as I aim to understand industry challenges and opportunities. As a token of appreciation, I’ll share a compiled report of the industry insights gathered from these discussions, which might benefit your ongoing work. Book 15 minutes call here: https://lnkd.in/d4MebpMB Thank you for considering this request. You can tag a friend in a comment or send me a DM. P.S. a brief 15-minute conversation or a referral to a knowledgeable contact would greatly aid our efforts to understand preclinical efficacy testing better. #Preclinical #organonchip #AI #pharma #Biotech

15 months in - perspectives on the most effective practices adopted by pharma, biotech and medtech companies regarding generative ai. We observe the most effective companies delivering on these 7 practices to achieve tangible results and rapid ROI. #generativeai #ROI #pharma #biotech

(Benefit-Risk Management / Small Sponsors / Public Mtg) If you're a small Sponsor (researcher, HCP, startup), this is a 4-hr mtg on ways to learn from lessons past in a joint webinar btwn FDA and NIH. I wish there were more details but topics do include reference to CMC, early stage drug, biologic, and device companies w/a FDA Q&A session. Enjoy. #fda #cder #drugs #biologics #cber #smid #drugdevelopment #cdrh #meddevices #cancerdrugs #oncologydrugs #startups #dht #digitalmedicine

Are you a drug developer and nearing completion of your preclinical trajectory?   Then you will have to consider your First-in-Human (FiH) study. Do you choose Phase 0 or do you choose Phase 1?   With this handy overview, you can quickly see the differences and decide which suits you best.   If you want to discuss what is best for you, feel free to contact us. We will be happy to brainstorm with you. Share your ideas in the comments or send us a message so we can schedule a personal meeting. #drugdiscovery #drugdevelopment #research #clinicaltrials